IL245045B - Selective pyy compounds and uses thereof - Google Patents

Selective pyy compounds and uses thereof

Info

Publication number
IL245045B
IL245045B IL245045A IL24504516A IL245045B IL 245045 B IL245045 B IL 245045B IL 245045 A IL245045 A IL 245045A IL 24504516 A IL24504516 A IL 24504516A IL 245045 B IL245045 B IL 245045B
Authority
IL
Israel
Prior art keywords
pyy compounds
selective
selective pyy
compounds
pyy
Prior art date
Application number
IL245045A
Other languages
Hebrew (he)
Other versions
IL245045A0 (en
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IL245045A0 publication Critical patent/IL245045A0/en
Publication of IL245045B publication Critical patent/IL245045B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
IL245045A 2013-11-15 2016-04-11 Selective pyy compounds and uses thereof IL245045B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13193082 2013-11-15
US201361906020P 2013-11-19 2013-11-19
EP14176725 2014-07-11
PCT/EP2014/074476 WO2015071355A1 (en) 2013-11-15 2014-11-13 Selective pyy compounds and uses thereof

Publications (2)

Publication Number Publication Date
IL245045A0 IL245045A0 (en) 2016-05-31
IL245045B true IL245045B (en) 2019-09-26

Family

ID=53056816

Family Applications (1)

Application Number Title Priority Date Filing Date
IL245045A IL245045B (en) 2013-11-15 2016-04-11 Selective pyy compounds and uses thereof

Country Status (15)

Country Link
US (2) US10246497B2 (en)
EP (1) EP3068421B1 (en)
JP (1) JP6602760B2 (en)
KR (1) KR20160075819A (en)
CN (1) CN105722526B (en)
AU (1) AU2014350197B2 (en)
BR (1) BR112016010383A2 (en)
CA (1) CA2929672A1 (en)
IL (1) IL245045B (en)
MX (1) MX369818B (en)
PL (1) PL3068421T3 (en)
RS (1) RS59026B1 (en)
SI (1) SI3068421T1 (en)
TW (1) TWI661835B (en)
WO (1) WO2015071355A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX345501B (en) 2010-12-16 2017-02-02 Novo Nordisk As Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid.
EP2827885B1 (en) 2012-03-22 2018-08-15 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
SMT201800492T1 (en) 2013-05-02 2018-11-09 Novo Nordisk As Oral dosing of glp-1 compounds
UY35548A (en) * 2013-05-02 2014-11-28 Glaxosmithkline Ip No 2 Ltd THERAPEUTIC PEPTIDES FOR THE TREATMENT OF METABOLIC DISORDERS.
EP3068795B1 (en) * 2013-11-15 2019-03-06 Novo Nordisk A/S Hpyy(1-36) having a beta-homoarginine substitution at position 35
AU2014350197B2 (en) 2013-11-15 2018-10-04 Novo Nordisk A/S Selective PYY compounds and uses thereof
AU2016275735B2 (en) 2015-06-12 2020-02-06 Novo Nordisk A/S Selective PYY compounds and uses thereof
KR20180135012A (en) * 2016-04-28 2018-12-19 노보 노르디스크 에이/에스 Sema Glutide in Cardiovascular Conditions
MA46780A (en) 2016-11-07 2019-09-11 Novo Nordisk As ESTERS WITH ACTIVE DCHBS OF PEG COMPOUNDS AND THEIR USE
CN109248323B (en) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 Acylated GLP-1 derivatives
JP2020527159A (en) 2017-07-19 2020-09-03 ノヴォ ノルディスク アー／エス EGF (A) analogs, their manufacture, formulation and use
TWI847306B (en) 2017-08-24 2024-07-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1 compositions and uses thereof
US20210171598A1 (en) 2017-12-01 2021-06-10 University Of Copenhagen Peptide hormone with one or more o-glycans
CA3087077A1 (en) * 2018-01-09 2019-07-18 Gila Therapeutics, Inc. Compositions and methods for treating metabolic diseases
EP4299118A3 (en) 2018-02-02 2024-04-10 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
GB2573145A (en) 2018-04-26 2019-10-30 Univ Ulster Peptides for metabolic disease
TWI705820B (en) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1 agonist compositions
TWI749381B (en) 2018-11-01 2021-12-11 美商美國禮來大藥廠 Protein tyrosine-tyrosine analogs and methods of using the same
JP2022543826A (en) * 2019-08-07 2022-10-14 ノヴォ ノルディスク アー／エス A solid composition containing a PYY compound and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
PE20221168A1 (en) 2019-11-11 2022-07-25 Boehringer Ingelheim Int NPY2 RECEPTOR AGONISTS
UA130066C2 (en) 2020-08-07 2025-10-29 Бьорінгер Інгельхайм Інтернаціональ Гмбх Soluble npy2 receptor agonists
MX2023005408A (en) * 2020-11-09 2023-07-25 Embark Biotech Aps Compounds and their use in treatment of tachykinin receptor mediated disorders.
US20240091318A1 (en) 2022-08-18 2024-03-21 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists
TW202535961A (en) * 2023-12-12 2025-09-16 美商卡默療法股份有限公司 Hybrid peptide compounds having a substituted tryptophan residue or a terminal substituent
TW202540152A (en) * 2023-12-12 2025-10-16 美商卡默療法股份有限公司 Hybrid peptide compounds having a modified lysine residue

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0692971A4 (en) 1993-03-29 1997-11-12 Univ Cincinnati PEPTIDE YY ANALOGS AND USES THEREOF
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
AU1159897A (en) 1996-11-13 1998-06-03 University Of Cincinnati, The Analogs of peptide yy and uses thereof
EP0908515A3 (en) 1997-09-16 2000-04-26 Smithkline Beecham Plc Pancreatic polypeptide
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
IL139913A0 (en) 1998-06-08 2002-02-10 Schering Corp Neuropeptide y5 receptor antagonists
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
CA2431800C (en) 2000-12-14 2014-07-08 Amylin Pharmaceuticals, Inc. Peptide yy and peptide yy agonists for treatment of metabolic disorders
US6589938B2 (en) 2001-06-29 2003-07-08 National University Of Singapore Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
BR0212985A (en) 2001-09-24 2005-08-30 Imp College Innovations Ltd Use of pyy or an agonist in the preparation of medicaments for treating disorders associated with overweight
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
EP1583549A4 (en) 2003-01-17 2006-10-04 Sod Conseils Rech Applic ANALYZES OF PEPTIDE YY
US7572581B2 (en) 2003-06-30 2009-08-11 Roche Molecular Systems, Inc. 2′-terminator nucleotide-related methods and systems
CN101380476A (en) 2003-09-19 2009-03-11 诺沃挪第克公司 Albumin-binding derivatives of therapeutic peptides
CA2539253A1 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
JP2007537981A (en) 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ Novel plasma protein affinity tag
BRPI0417684A (en) 2003-12-18 2007-03-20 Novo Nordisk As compound, pharmaceutical composition, and use of a compound
BRPI0507594A (en) 2004-02-11 2007-07-03 Amylin Pharmaceuticals Inc hybrid polypeptides with selectable properties
US8603969B2 (en) 2004-02-11 2013-12-10 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same
ATE519495T1 (en) 2004-03-17 2011-08-15 7Tm Pharma As Y4-SELECTIVE RECEPTOR AGONIST PP2-36 FOR THERAPEUTIC PROCEDURES
CA2559838A1 (en) 2004-03-17 2005-09-29 7Tm Pharma A/S Y2 selective receptor agonists for therapeutic interventions
CA2560166A1 (en) 2004-03-17 2005-09-29 7Tm Pharma A/S Y2/y4 selective receptor agonists for therapeutic interventions
CN101361967A (en) 2004-03-17 2009-02-11 7Tm制药联合股份有限公司 Y2/Y4 selective receptor agonists for therapeutic interventions
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
ES2542228T3 (en) 2004-07-08 2015-08-03 Novo Nordisk A/S Polypeptide extension tags comprising a tetrazole moiety
US7994119B2 (en) 2004-07-19 2011-08-09 University Of Cincinnati Compounds for control of appetite
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
US7410949B2 (en) 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
US20090054326A1 (en) 2005-07-11 2009-02-26 Nastech Pharmaceutical Company Inc. Formulations for enhanced mucosal delivery of pyy
CN101222942A (en) 2005-07-18 2008-07-16 诺沃-诺迪斯克有限公司 Peptides for the Treatment of Obesity
EP1934254A1 (en) 2005-09-21 2008-06-25 7TM Pharma A/S Y4 selective receptor agonists for therapeutic interventions
BRPI0520566A2 (en) 2005-09-21 2009-05-19 7Tm Pharma As selective y2 receptor agonists for therapeutic interventions
WO2007065808A2 (en) 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor-agonists
JP2009519296A (en) 2005-12-14 2009-05-14 ノボ・ノルデイスク・エー／エス Polypeptide extension tag
US20070197445A1 (en) 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
CN101432025B (en) 2006-03-21 2012-04-04 安米林药品公司 Peptide-peptidase inhibitor conjugates and methods of use
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
US20090099074A1 (en) 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
JP2010516652A (en) 2007-01-18 2010-05-20 ノボ・ノルデイスク・エー／エス Novel peptides used in the treatment of obesity
US20100022446A1 (en) 2007-01-18 2010-01-28 Novo Nordisk A/S Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
GB0708226D0 (en) 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
JP2010533157A (en) 2007-07-09 2010-10-21 インペリアル イノベーションズ リミテッド Human pancreatic polypeptide (HPP) analogs and their effects on feeding behavior
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
JP2010538981A (en) 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト The peptide His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys as a therapeutic agent used alone or in combination with the peptide Gly-Arg-Gly-Asp-Asn-Pro-OH -Use of Phe
WO2009042922A2 (en) 2007-09-27 2009-04-02 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
RU2504550C2 (en) 2008-05-16 2014-01-20 Ново Нордиск А/С Long-acting agonists of receptors y2 and(or) y4
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
GB0817067D0 (en) 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment
CA2741921A1 (en) * 2008-11-05 2010-05-14 F. Hoffmann-La Roche Ag Neuropeptide-2-receptor (y-2r) agonists and uses thereof
JP5584236B2 (en) 2009-02-20 2014-09-03 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ Cytotoxic conjugates having neuropeptide Y receptor binding compounds
EP2477643A1 (en) * 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
CA2776302A1 (en) 2009-10-13 2011-04-21 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor (y-2r) agonists
EP2498800A1 (en) * 2009-11-13 2012-09-19 Novo Nordisk A/S Long-acting y2 receptor agonists
EP2560675A1 (en) 2010-04-20 2013-02-27 Novo Nordisk A/S Long-acting gastrin derivatives
KR101927068B1 (en) * 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 Sequential Combination Therapy by the Weight Reducing Treatment Followed by the DPP-4 Inhibitor
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
WO2013178490A1 (en) 2012-05-29 2013-12-05 Novo Nordisk A/S Pancreatic polypeptide compounds and use
UY35548A (en) 2013-05-02 2014-11-28 Glaxosmithkline Ip No 2 Ltd THERAPEUTIC PEPTIDES FOR THE TREATMENT OF METABOLIC DISORDERS.
AU2014350197B2 (en) 2013-11-15 2018-10-04 Novo Nordisk A/S Selective PYY compounds and uses thereof
EP3068795B1 (en) 2013-11-15 2019-03-06 Novo Nordisk A/S Hpyy(1-36) having a beta-homoarginine substitution at position 35
AU2016275735B2 (en) * 2015-06-12 2020-02-06 Novo Nordisk A/S Selective PYY compounds and uses thereof

Also Published As

Publication number Publication date
MX369818B (en) 2019-11-22
IL245045A0 (en) 2016-05-31
JP2017505284A (en) 2017-02-16
PL3068421T3 (en) 2019-11-29
US20150152150A1 (en) 2015-06-04
TW201605467A (en) 2016-02-16
US9085637B2 (en) 2015-07-21
WO2015071355A1 (en) 2015-05-21
RS59026B1 (en) 2019-08-30
US20160289283A1 (en) 2016-10-06
BR112016010383A2 (en) 2017-12-05
CN105722526A (en) 2016-06-29
AU2014350197A1 (en) 2016-05-05
AU2014350197B2 (en) 2018-10-04
CN105722526B (en) 2020-12-08
US10246497B2 (en) 2019-04-02
KR20160075819A (en) 2016-06-29
CA2929672A1 (en) 2015-05-21
EP3068421B1 (en) 2019-04-17
MX2016006053A (en) 2016-08-17
EP3068421A1 (en) 2016-09-21
JP6602760B2 (en) 2019-11-06
TWI661835B (en) 2019-06-11
SI3068421T1 (en) 2019-08-30

Similar Documents

Publication Publication Date Title
IL274355B (en) Aza-pyridone compounds and uses thereof
IL276113B (en) E-vaping section and e-vaping device
IL245045B (en) Selective pyy compounds and uses thereof
DK3689865T3 (en) Hidtil ukendte aminopyrimidinderivater
IL240275B (en) Selective antisense compounds and uses thereof
ZA201603549B (en) New pesticidal compounds and uses
GB201323008D0 (en) Compounds and uses thereof
GB201317802D0 (en) SmartHaler patent application
GB201300707D0 (en) Compounds and processes
IL244214A0 (en) Thienopiperidine derivative and use thereof
GB201307233D0 (en) Compounds and uses thereof
DK3056208T3 (en) Immunpotentiator
ZA201601880B (en) Hetero-transglycosylase and uses thereof
ZA201600015B (en) Anti-fibrogenic compounds, methods and uses thereof
GB201309180D0 (en) Compounds and Their Uses
GB201301329D0 (en) Fluidfoil
GB201314610D0 (en) Compounds and their uses
GB201306248D0 (en) Compounds and their uses
PT3068421T (en) Selective pyy compounds and uses thereof
AU5375P (en) Sungeloho Angelonia angustifolia
AU5374P (en) Sungelodepi Angelonia angustifolia
AU5373P (en) Sungelobu Angelonia angustifolia
GB201309248D0 (en) Compounds and combinations
GB201323005D0 (en) Compounds and uses thereof
AU4977P (en) Harrosy Gaura lindheimeri

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees